Scorpion Therapeutics
Oct 26, 2020 · Scorpion is a pioneering clinical-stage oncology company redefining the frontier of precision medicine to deliver transformational therapies for larger populations of patients with cancer
About - Scorpion Therapeutics
At Scorpion Therapeutics, we are expanding the reach of precision medicine to more people with untreatable or treatment-resistant cancer.
Pipeline - Scorpion Therapeutics
Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline
News - Scorpion Therapeutics
Oct 10, 2023 · Scorpion Therapeutics Accelerates Precision Oncology 2.0 for More Patient Populations. Read More
Scorpion Therapeutics Enters Agreement With Astrazeneca To …
– January 13, 2022 – Scorpion Therapeutics, Inc. (“Scorpion”), a next-generation oncology company pioneering Precision Oncology 2.0, today announced a collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to ...
Scorpion Therapeutics to Present STX-478 Initial Phase 1/2 Data at …
Scorpion’s Phase 1/2 clinical trial is a multi-center, global, open-label study designed to evaluate the safety and tolerability of STX-478 in multiple ascending doses for patients with locally advanced or metastatic HR+/HER2- breast cancer and other solid tumors driven by …
Scorpion Therapeutics Provides Clinical Program Updates for Its …
Scorpion’s current pipeline, led by STX-478, our mutant-selective PI3Kα program, consists of three internally discovered clinical product candidates and multiple discovery-stage programs. Our focus is on solving current gaps in therapeutic options for patients with cancer by discovering and developing product candidates selective against ...
Science – Scorpion Therapeutics
Driven by advances in cancer biology, medicinal chemistry and data sciences over the last two decades, the field of cancer therapy has entered a new era of more targeted, genetic-based approaches.
Scorpion Therapeutics Announces $150 Million Series C Financing …
Scorpion Therapeutics, Inc., a pioneering clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, today announced the closing of a $150 million Series C financing.
Scorpion Therapeutics Presents Initial Clinical Data from Its Phase …
Scorpion’s Phase 1/2 clinical trial is a multi-center, global, open-label study designed to evaluate the safety and tolerability of STX-478 in multiple ascending doses for patients with locally advanced or metastatic HR+/HER2- breast cancer and other solid tumors driven by …